Compare SLND & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLND | MREO |
|---|---|---|
| Founded | 1900 | 2015 |
| Country | United States | United Kingdom |
| Employees | 2100 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.6M | 67.5M |
| IPO Year | N/A | 2017 |
| Metric | SLND | MREO |
|---|---|---|
| Price | $0.87 | $0.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $4.00 | $3.13 |
| AVG Volume (30 Days) | 132.2K | ★ 1.5M |
| Earning Date | 03-26-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.20 |
| 52 Week High | $5.34 | $2.94 |
| Indicator | SLND | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 34.82 |
| Support Level | N/A | $0.20 |
| Resistance Level | $4.57 | $0.42 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 41.22 | 22.62 |
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).